Developer docs
API playgroundTry for free, no card

Search company profiles

Proxygen

Full company profile

uuid00089ef

Namestring
Proxygen
Legal namestring
Proxygen GmbH
Websiteurl
proxygen.com
Company typeenum
Private
Founded yearint
2020
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersVienna, Austria
HQ citystring
Vienna
HQ countrystring
Austria
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular glue degraders, targeted protein degradation, induced proximity therapeutics, oncology drug discovery, undruggable protein targets
Industry3 codes
PRIMARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Targeted Protein Degradation Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Partnerships and Licensing
TypeLicensing Royalties
Description

Proxygen generates revenue through strategic research collaboration and license agreements with pharmaceutical companies. These arrangements provide upfront payments, research and development funding, success-based milestone payments tied to preclinical, clinical, regulatory, and commercial achievements, plus royalty payments on net sales of developed products.

proxygen.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Proxygen develops molecular glue degraders and induced proximity therapeutics using a proprietary, ligase-agnostic discovery platform that integrates genomics, proteomics, and biochemistry to systematically identify degraders against previously undruggable proteins. Its pipeline includes a first-in-class oral p300 glue degrader for transcription-driven cancers and a brain-penetrant CDK12/Cyclin K degrader for HER2-driven cancers with CNS involvement, advanced through strategic research collaborations and license agreements with global pharmaceutical companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Over 80% of human proteins are not accessible via traditional drug approaches and are generally considered 'undruggable' - Proxygen's glue degraders can address these targets
+1 more record
Product overview1 text field

Proxygen is a Vienna-based biotechnology company pioneering the discovery and development of molecular glue degraders and induced proximity therapeutics. The company's portfolio centers on two lead clinical-stage programs: the p300 molecular glue degrader for transcription-driven cancers and the CDK12 (Cyclin K) brain-penetrant degrader for HER2-driven cancers with CNS involvement. These programs are powered by Proxygen's proprietary discovery platform that enables systematic identification of glue degraders against previously undruggable targets. The company also maintains partnered programs with MSD (Merck & Co) and is expanding its platform beyond degradation into broader induced proximity mechanisms.

Product and service4 records
1p300 Molecular Glue Degrader Program
CategoryOncology therapeutic program
Description

First-in-class oral molecular glue degrader targeting the transcriptional co-activator p300 with sub-nanomolar potency and differentiated covalent glue pharmacology, designed to address transcription-driven cancers including prostate, lung, and bladder cancer through catalytic degradation and PK/PD decoupling.

2CDK12 Molecular Glue Degrader Program
CategoryOncology therapeutic program
Description

First-in-class brain-penetrant molecular glue degrader that inactivates CDK12 via Cyclin K degradation, with high selectivity across the CDK family, designed to address HER2-driven cancers with CNS metastases and transcriptional dependencies in HER2-driven cancers.

3Molecular Glue Degrader Discovery Platform
CategoryDrug discovery platform
Description

Proprietary, highly versatile discovery engine enabling specific and unbiased identification of molecular glue degraders against difficult-to-drug or completely undruggable targets at large scale, integrating genomic, proteomic, and biochemical technologies through a ligase-agnostic screening approach.

4MSD Partnered Programs
CategoryPartnered therapeutic programs
Description

Undisclosed molecular glue degrader programs being co-developed with MSD (Merck & Co Inc.) targeting multiple therapeutic areas under a multi-year research collaboration and license agreement.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-08-26
Description

Strategic research collaboration combining Proxygen's validated glue degrader discovery platform with EPFL's pioneering work in AI and structural modeling for protein design. Partnership aims to build next-generation discovery paradigm bridging high-throughput in vitro screening with state-of-the-art in silico design to predict and validate neosubstrate-ligase interactions and design chemical matter for targeted protein degradation.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-04-05
Description

Multi-year research collaboration and license agreement to jointly identify and develop molecular glue degraders against multiple therapeutic targets. Proxygen received upfront payment and is eligible for future payments of up to $2.55 billion based on achievement of specified research, development, and commercial milestones across all programs, plus royalties on net sales.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-06-02
Description

Strategic multi-year research collaboration and license agreement to jointly identify and develop molecular glue degraders up to clinical candidate stage. Proxygen eligible to receive up to €495 million ($554 million) in R&D funding, upfront and success-based preclinical, clinical, regulatory, and commercial milestones, plus tiered royalties.

4Boehringer Ingelheim
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-12-07
Description

Collaboration and license agreement to enable identification of molecular glue degraders against various oncogenic targets, complementing Boehringer Ingelheim's cancer research strategy. Proxygen entitled to receive upfront payments, R&D support, milestone-gated development payments, and tiered royalties based on future commercial sales.

proxygen.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Amgen is a large pharmaceutical company with internal TPD initiatives and a relevant oncology-focused dealmaker. Comparable in being a potential partner/competitor for protein degrader programs in oncology indications similar to Proxygen's lead targets.

TypeEmerging player
Description

Neomorph is a private biotech developing induced proximity-based molecular glues and degraders, founded by degrader pioneers. Emerging player with significant overlap to Proxygen's glue degrader discovery focus, though still at earlier stages.

TypeDirect peer
Description

Monte Rosa is a clinical-stage biotech developing molecular glue degraders for cancer and other diseases, founded by prominent TPD researchers. It is one of the closest pure-play molecular glue competitors to Proxygen and targets a similar set of undruggable oncology targets.

TypeBroad incumbent
Description

Novartis is a major pharmaceutical company with active TPD programs and historical investments in protein degradation (including through collaborations and internal R&D). A potential strategic partner or acquirer for Proxygen's platform and lead programs.

TypeDirect peer
Description

Arvinas is a clinical-stage biotech pioneering targeted protein degradation via PROTACs and molecular glue degraders, with partnered programs (including with Pfizer) and internal oncology pipeline. It is the most established public peer in the TPD space and competes directly for both targets and pharma partnerships.

TypeDirect peer
Description

C4 Therapeutics is a clinical-stage biotech developing targeted protein degraders (TORPEDO platform) for oncology and other diseases, with partnerships including Roche, Biogen, and Merck KGaA's Calyx. Direct competitor in molecular glue and bifunctional degrader discovery.

TypeDirect peer
Description

Kymera is a clinical-stage biotech developing heterobifunctional degraders and molecular glue degraders across oncology and immunology, with pharma partnerships (including Sanofi). It directly competes with Proxygen in the TPD modality space and for undruggable oncology targets.

TypeEmerging player
Description

Plexium is a private biotech developing targeted protein degraders using a proprietary DEL-Plex platform for E3 ligase ligand discovery. Comparable in scale and stage to Proxygen and addresses similar undruggable oncology targets.

TypeEmerging player
Description

Foghorn is a clinical-stage biotech focused on chromatin biology and dysregulated gene expression, with emerging protein degrader programs. Adjacent to Proxygen's transcription-driven cancer focus (e.g., p300 program) and competes for similar oncology targets.

10Bristol Myers Squibb
TypeBroad incumbent
Description

BMS is a large pharmaceutical company with significant internal TPD efforts through its Avilomics and Montelino platforms, and a major customer/partner candidate in the degrader space. Competes for similar oncology programs and partnership slots that Proxygen targets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Proxygen

Targeted Protein Degradation Therapeuticsproxygen.com

Proxygen firmographics

Firmographics
Name
Proxygen
Legal name
Proxygen GmbH
Website
https://proxygen.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Proxygen industry classification

Industry
Product category
Targeted Protein Degradation Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Molecular glue degraders
  • Targeted protein degradation
  • Induced proximity therapeutics
  • Oncology drug discovery
  • Undruggable protein targets

Where Proxygen is headquartered

Location

Headquarters

HQ city
Vienna
HQ country
Austria
HQ region
Europe

Offices1 record

Markets served

Proxygen business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

  1. Pharmaceutical Partnerships and Licensing: Proxygen generates revenue through strategic research collaboration and license agreements with pharmaceutical companies. These arrangements provide upfront payments, research and development funding, success-based milestone payments tied to preclinical, clinical, regulatory, and commercial achievements, plus royalty payments on net sales of developed products.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Proxygen product offering

Product offering

Core offering

Proxygen develops molecular glue degraders and induced proximity therapeutics using a proprietary, ligase-agnostic discovery platform that integrates genomics, proteomics, and biochemistry to systematically identify degraders against previously undruggable proteins. Its pipeline includes a first-in-class oral p300 glue degrader for transcription-driven cancers and a brain-penetrant CDK12/Cyclin K degrader for HER2-driven cancers with CNS involvement, advanced through strategic research collaborations and license agreements with global pharmaceutical companies.

Product overview

Proxygen is a Vienna-based biotechnology company pioneering the discovery and development of molecular glue degraders and induced proximity therapeutics. The company's portfolio centers on two lead clinical-stage programs: the p300 molecular glue degrader for transcription-driven cancers and the CDK12 (Cyclin K) brain-penetrant degrader for HER2-driven cancers with CNS involvement. These programs are powered by Proxygen's proprietary discovery platform that enables systematic identification of glue degraders against previously undruggable targets. The company also maintains partnered programs with MSD (Merck & Co) and is expanding its platform beyond degradation into broader induced proximity mechanisms.

Differentiator

Problem solved

Functional benefit

Products and services

  • p300 Molecular Glue Degrader Program First-in-class oral molecular glue degrader targeting the transcriptional co-activator p300 with sub-nanomolar potency and differentiated covalent glue pharmacology, designed to address transcription-driven cancers including prostate, lung, and bladder cancer through catalytic degradation and PK/PD decoupling.
  • CDK12 Molecular Glue Degrader Program First-in-class brain-penetrant molecular glue degrader that inactivates CDK12 via Cyclin K degradation, with high selectivity across the CDK family, designed to address HER2-driven cancers with CNS metastases and transcriptional dependencies in HER2-driven cancers.
  • Molecular Glue Degrader Discovery Platform Proprietary, highly versatile discovery engine enabling specific and unbiased identification of molecular glue degraders against difficult-to-drug or completely undruggable targets at large scale, integrating genomic, proteomic, and biochemical technologies through a ligase-agnostic screening approach.
  • MSD Partnered Programs Undisclosed molecular glue degrader programs being co-developed with MSD (Merck & Co Inc.) targeting multiple therapeutic areas under a multi-year research collaboration and license agreement.

Quantifiable outcome

  • Over 80% of human proteins are not accessible via traditional drug approaches and are generally considered 'undruggable' - Proxygen's glue degraders can address these targets
  • +1 more outcomes

Companies that use Proxygen

Customer profile

Segments2 records

Ideal customer profiles1 record

Proxygen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Proxygen partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered flagship and core.

  • EPFL (Swiss Federal Institute of Technology in Lausanne)flagshipStrategic or Co-development Partner · 26 August 2025Strategic research collaboration combining Proxygen's validated glue degrader discovery platform with EPFL's pioneering work in AI and structural modeling for protein design. Partnership aims to build next-generation discovery paradigm bridging high-throughput in vitro screening with state-of-the-art in silico design to predict and validate neosubstrate-ligase interactions and design chemical matter for targeted protein degradation.
  • MSD (Merck & Co Inc.)coreStrategic or Co-development Partner · 5 April 2023Multi-year research collaboration and license agreement to jointly identify and develop molecular glue degraders against multiple therapeutic targets. Proxygen received upfront payment and is eligible for future payments of up to $2.55 billion based on achievement of specified research, development, and commercial milestones across all programs, plus royalties on net sales.
  • Merck KGaAcoreStrategic or Co-development Partner · 2 June 2022Strategic multi-year research collaboration and license agreement to jointly identify and develop molecular glue degraders up to clinical candidate stage. Proxygen eligible to receive up to €495 million ($554 million) in R&D funding, upfront and success-based preclinical, clinical, regulatory, and commercial milestones, plus tiered royalties.
  • Boehringer IngelheimcoreStrategic or Co-development Partner · 7 December 2020Collaboration and license agreement to enable identification of molecular glue degraders against various oncogenic targets, complementing Boehringer Ingelheim's cancer research strategy. Proxygen entitled to receive upfront payments, R&D support, milestone-gated development payments, and tiered royalties based on future commercial sales.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Proxygen competitors and assessment

Company assessment

Broad incumbents

  • Amgen: Amgen is a large pharmaceutical company with internal TPD initiatives and a relevant oncology-focused dealmaker. Comparable in being a potential partner/competitor for protein degrader programs in oncology indications similar to Proxygen's lead targets.
  • Novartis: Novartis is a major pharmaceutical company with active TPD programs and historical investments in protein degradation (including through collaborations and internal R&D). A potential strategic partner or acquirer for Proxygen's platform and lead programs.
  • Bristol Myers Squibb: BMS is a large pharmaceutical company with significant internal TPD efforts through its Avilomics and Montelino platforms, and a major customer/partner candidate in the degrader space. Competes for similar oncology programs and partnership slots that Proxygen targets.

Emerging players

  • Neomorph: Neomorph is a private biotech developing induced proximity-based molecular glues and degraders, founded by degrader pioneers. Emerging player with significant overlap to Proxygen's glue degrader discovery focus, though still at earlier stages.
  • Plexium: Plexium is a private biotech developing targeted protein degraders using a proprietary DEL-Plex platform for E3 ligase ligand discovery. Comparable in scale and stage to Proxygen and addresses similar undruggable oncology targets.
  • Foghorn Therapeutics: Foghorn is a clinical-stage biotech focused on chromatin biology and dysregulated gene expression, with emerging protein degrader programs. Adjacent to Proxygen's transcription-driven cancer focus (e.g., p300 program) and competes for similar oncology targets.

Direct peers

  • Monte Rosa Therapeutics: Monte Rosa is a clinical-stage biotech developing molecular glue degraders for cancer and other diseases, founded by prominent TPD researchers. It is one of the closest pure-play molecular glue competitors to Proxygen and targets a similar set of undruggable oncology targets.
  • Arvinas: Arvinas is a clinical-stage biotech pioneering targeted protein degradation via PROTACs and molecular glue degraders, with partnered programs (including with Pfizer) and internal oncology pipeline. It is the most established public peer in the TPD space and competes directly for both targets and pharma partnerships.
  • C4 Therapeutics: C4 Therapeutics is a clinical-stage biotech developing targeted protein degraders (TORPEDO platform) for oncology and other diseases, with partnerships including Roche, Biogen, and Merck KGaA's Calyx. Direct competitor in molecular glue and bifunctional degrader discovery.
  • Kymera Therapeutics: Kymera is a clinical-stage biotech developing heterobifunctional degraders and molecular glue degraders across oncology and immunology, with pharma partnerships (including Sanofi). It directly competes with Proxygen in the TPD modality space and for undruggable oncology targets.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Proxygen social profiles

Digital presence

Proxygen compliance and trust

Trust signal

Compliance1 record

Proxygen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Proxygen leadership team

Management profile

Number of profiles

Profiles4 records

Proxygen funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Proxygen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Proxygen

What does Proxygen do?

Proxygen develops molecular glue degraders and induced proximity therapeutics using a proprietary, ligase-agnostic discovery platform that integrates genomics, proteomics, and biochemistry to systematically identify degraders against previously undruggable proteins. Its pipeline includes a first-in-class oral p300 glue degrader for transcription-driven cancers and a brain-penetrant CDK12/Cyclin K degrader for HER2-driven cancers with CNS involvement, advanced through strategic research collaborations and license agreements with global pharmaceutical companies.

Is Proxygen a public or private company?

Proxygen is a private company. It is classified as unknown and is currently operating.

When was Proxygen founded?

Proxygen was founded in 2020. It employs 11 to 50 people.

Where is Proxygen based?

Proxygen is headquartered in Vienna, Austria, in the Europe region.

How does Proxygen make money?

One revenue line is on record: pharmaceutical Partnerships and Licensing.

Who are Proxygen's main competitors?

Broad incumbents on record are Amgen, Novartis and Bristol Myers Squibb. Emerging players are Neomorph, Plexium and Foghorn Therapeutics. Direct peers are Monte Rosa Therapeutics, Arvinas, C4 Therapeutics and Kymera Therapeutics.

Does Proxygen have an API?

No public API is recorded for Proxygen.

What industry is Proxygen in?

Proxygen's product category is Targeted Protein Degradation Therapeutics. Its primary akta.pro industry code is HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization), with a secondary code of HLAAAAAJ, Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Labiotech.euAre we ready for the next wave of proximity degraders?Proxygen's next-generation molecular glue degraders use covalent pharmacology to degrade disease-causing proteins, with p300 and CDK12 programs expected to enter IND-enabling studies next year. The company's approach targets undruggable proteins, and other firms like Halda and Fortitude are developing RIPTACs and Glue-DACs to address ADC resistance.GlobeNewswireProxygen Expands Platform Beyond Degradation to Build Next-Generation Induced Proximity TherapeuticsProxygen announced expansion beyond targeted protein degradation into induced proximity therapeutics, advancing two lead molecular glue degrader programs, p300 and CDK12, toward clinical development. The p300 program targets a transcriptional co-activator in multiple cancers, while CDK12 is a brain-penetrant degrader for HER2-driven cancers. The company plans to advance these programs toward development candidate nomination and IND-enabling studies over the next 12 to 18 months.STATUp and down the ladder: The latest comings and goingsThe article reports that Proxygen has hired Chiara Conti as their new chief scientific officer, with her previous experience at Blueprint Medicines.GlobeNewswireProxygen Appoints Chiara Conti, Ph.D. as Chief Scientific Officer to Drive Clinical Translation and Expand Induced Proximity Platform Beyond DegradationProxygen appointed Chiara Conti, Ph.D., as Chief Scientific Officer, bringing her from Blueprint Medicines where she identified four development candidates in seven years. She will lead the transition to clinical-stage execution and expand the induced proximity platform beyond degradation. The company will continue investing in its degradation platform while exploring new effector classes.The Pharma LetterProxygen appoints Chiara Conti as CSOProxygen appointed Chiara Conti as chief scientific officer, bringing her from Blueprint Medicines. She identified four development candidates in seven years, two advanced to IND, and established the company's TPD platform. She will lead the transition to clinical-stage execution.GlobeNewswireProxygen and EPFL Launch Strategic Collaboration to Advance AI-Driven Glue DiscoveryProxygen and EPFL announced a strategic collaboration to combine Proxygen's glue degrader discovery platform with EPFL's AI-driven protein design. The partnership aims to predict and validate neosubstrate-ligase interactions and design chemical matter for targeted protein degradation. The collaboration is expected to accelerate glue degrader development across a broad target landscape.GlobeNewswireProxygen Announces Formation of Scientific Advisory BoardProxygen announced the formation of its scientific advisory board, comprising Brenda Schulman, Giulio Draetta, Georg Winter, and Stefan Kubicek. The board will guide the company's molecular glue degrader programs toward clinical development, with collaborations with Merck, Boehringer Ingelheim, and Merck KGaA.GlobeNewswireFierce Biotech Names Proxygen a “Fierce 15” Biotech Company of 2023Proxygen was named one of Fierce Biotech's 2023 Fierce 15 biotech companies. The company develops molecular glue degraders to target undruggable proteins, with partnerships including Boehringer Ingelheim, Merck KGaA, and MSD. It aims to advance internal programs toward clinical development.BioSpaceProxygen Snags Third Big Pharma Partner in Deal Valued at $2.55BProxygen added Merck to its partner roster, receiving an undisclosed upfront payment plus potential $2.55 billion in milestones. The deal is the company's largest, following a $554 million collaboration with Merck KGaA in 2022. Proxygen will expand its headcount to support the partnership.